Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06065930

Adaptive Mechanisms In GRown up ObeSity Study (AMIGROS)

Mechanistic Studies in Human Subcutaneous Adipose Tissue

Status
Recruiting
Phase
Study type
Observational
Enrollment
45 (estimated)
Sponsor
Vastra Gotaland Region · Other Government
Sex
All
Age
40 Years – 70 Years
Healthy volunteers
Accepted

Summary

The investigator recently showed that the glycan-binding adipokine galectin-1 increased during overfeeding and that galectin-1 independently could predict type 2 diabetes. Further, the molecules that induce insulin release in the fasting state when blood glucose is normal remain elusive. It is possible that galectin-1 is involved in adaptive mechanisms in adipose tissue in obese subjects.

Detailed description

The investigator will define adaptive mechanisms in adipose tissue associated with galectin-1 in obese insulin-sensitive (Ob-IS) subjects compared with obese insulin-resistant (Ob-IR) subjects and lean healthy controls. Further, the investigator will study molecules secreted from adipose tissue that might trigger insulin secretion when blood glucose is normal. The investigator hypothesizes that Ob-IS subjects keep fatty acid levels normal through an adaptive response in adipose tissue that involves up-regulation of galectin-1 for dampening of immune cell activity and stimulation of lipolysis.

Conditions

Interventions

TypeNameDescription
DEVICESubcutaneous microdialysisGroup with Ob-IS participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1. Group with Ob-IR participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1. Group with Leans, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.

Timeline

Start date
2023-05-05
Primary completion
2025-12-31
Completion
2028-12-31
First posted
2023-10-04
Last updated
2023-10-04

Locations

1 site across 1 country: Sweden

Source: ClinicalTrials.gov record NCT06065930. Inclusion in this directory is not an endorsement.